Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-0294
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database ; volume:5 ; number:1 ; day:7 ; month:10 ; year:2019 ; pages:1-4 ; date:12.2019
Journal of pharmaceutical health care and sciences ; 5, Heft 1 (7.10.2019), 1-4, 12.2019
- Creator
-
Niinomi, Iku
Hosohata, Keiko
Mori, Yasuhiro
Yamaguchi, Yuki
Wakabayashi, Tomohito
Uchida, Mayako
Iwanaga, Kazunori
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40780-019-0149-z
- URN
-
urn:nbn:de:101:1-2020020819535181780345
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Niinomi, Iku
- Hosohata, Keiko
- Mori, Yasuhiro
- Yamaguchi, Yuki
- Wakabayashi, Tomohito
- Uchida, Mayako
- Iwanaga, Kazunori
- SpringerLink (Online service)
Other Objects (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis